Palliative Prostate Artery Embolization for Prostate Cancer: A Case Series

19 Citationer (Scopus)


INTRODUCTION: Prostate artery embolization (PAE) is recognized as a treatment for lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia. LUTS and urinary retention are common in men with prostate cancer (PCa). The purpose of this study was to estimate the efficacy and safety of palliative PAE on LUTS or urinary retention in men with advanced PCa.

MATERIALS AND METHODS: This prospective, single-center trial was conducted from March 2017 to November 2018. The trial protocol was registered online ( Identifier: NCT03104907). Only men with advanced PCa suffering from LUTS or urinary retention were included. The primary outcome was the ability to void without a catheter and International Prostate Symptom Score (IPSS) in non-catheter-dependent patients. The paired t test was used to analyze changes from baseline with 95% confidence intervals (CI). A p value < 0.05 was considered statistically significant.

RESULTS: Seventeen patients were assessed for eligibility, and 15 patients with a mean age of 73.8 years were enrolled. Four men did not complete follow-up: cancer-related death (n = 2), lost to follow-up (n = 1), and unsuccessful embolization due to severe atherosclerosis (n = 1). Bilateral embolization was achieved in ten cases, and urinary retention resolved in one of six patients. LUTS improved in the remaining (n = 5) patients by a mean 12.2-point reduction in IPSS (95% CI - 23.53; - 0.87). According to the CIRSE classification, two grade 1 and two grade 3 complications occurred.

CONCLUSION: In this study, palliative PAE was safe and efficient for treatment for LUTS associated with PCa.

LEVEL OF EVIDENCE: Level 4, Case Series. Trial registration Identifier: NCT03104907.

TidsskriftCardiovascular and Interventional Radiology
Udgave nummer10
Sider (fra-til)1405-1412
Antal sider8
StatusUdgivet - 15 okt. 2019


Dyk ned i forskningsemnerne om 'Palliative Prostate Artery Embolization for Prostate Cancer: A Case Series'. Sammen danner de et unikt fingeraftryk.